scholarly journals Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes

2015 ◽  
Vol 183 (3) ◽  
pp. 350-357 ◽  
Author(s):  
M. J. Haller ◽  
M. A. Atkinson ◽  
C. H. Wasserfall ◽  
T. M. Brusko ◽  
C. E. Mathews ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Immunological Tolerance ◽  
Recent Onset ◽  
Onset Type

scholarly journals Verapamil and beta cell function in adults with recent-onset type 1 diabetes

2018 ◽  
Vol 24 (8) ◽  
pp. 1108-1112 ◽  
Author(s):  
Fernando Ovalle ◽  
Tiffany Grimes ◽  
Guanlan Xu ◽  
Anish J. Patel ◽  
Truman B. Grayson ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Recent Onset ◽  
Onset Type

scholarly journals Improved Preservation of Residual Beta Cell Function by Atorvastatin in Patients with Recent Onset Type 1 Diabetes and High CRP Levels (DIATOR Trial)

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33108 ◽  
Author(s):  
Alexander Strom ◽  
Hubert Kolb ◽  
Stephan Martin ◽  
Christian Herder ◽  
Marie-Christine Simon ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Recent Onset ◽  
Onset Type

scholarly journals A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes

2013 ◽  
Vol 32 (6) ◽  
pp. 911-917 ◽  
Author(s):  
Asal Ataie-Jafari ◽  
Seng-Cheong Loke ◽  
Asmah B. Rahmat ◽  
Bagher Larijani ◽  
Farzaneh Abbasi ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Controlled Trial ◽  
Recent Onset ◽  
Onset Type

scholarly journals Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route

2020 ◽  
Vol 21 (5) ◽  
pp. 1598 ◽  
Author(s):  
Johnny Ludvigsson
Keyword(s):  
Type 1 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Human Subjects ◽  
Subcutaneous Administration ◽  
Acid Decarboxylase ◽  
Recent Onset ◽  
Prevention Trials

Autoantigen treatment has been tried for the prevention of type 1 diabetes (T1D) and to preserve residual beta-cell function in patients with a recent onset of the disease. In experimental animal models, efficacy was good, but was insufficient in human subjects. Besides the possible minor efficacy of peroral insulin in high-risk individuals to prevent T1D, autoantigen prevention trials have failed. Other studies on autoantigen prevention and intervention at diagnosis are ongoing. One problem is to select autoantigen/s; others are dose and route. Oral administration may be improved by using different vehicles. Proinsulin peptide therapy in patients with T1D has shown possible minor efficacy. In patients with newly diagnosed T1D, subcutaneous injection of glutamic acid decarboxylase (GAD) bound to alum hydroxide (GAD-alum) can likely preserve beta-cell function, but the therapeutic effect needs to be improved. Intra-lymphatic administration may be a better alternative than subcutaneous administration, and combination therapy might improve efficacy. This review elucidates some actual problems of autoantigen therapy in the prevention and/or early intervention of type 1 diabetes.

Sign in / Sign up

Export Citation Format

Share Document